[Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway]

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Non-small cell lung cancer (NSCLC) remains a significant challenge, with many patients unresponsive to current targeted therapies.
• Immune checkpoint inhibitors targeting the PD1/PDL1 pathway offer a novel therapeutic strategy by restoring the immune system's anti-tumor response.
• The interaction between PD1 on lymphocytes and PDL1 on antigen-presenting cells leads to immune tolerance, hindering anti-tumor immunity.

Purpose of the Study:

• To evaluate the efficacy and safety of anti-PD1 and anti-PDL1 antibodies in NSCLC treatment.
• To explore the potential of immune modulation as a therapeutic approach for NSCLC.

Main Methods:

• Review of Phase I/II clinical trial data for anti-PD1 (nivolumab) and anti-PDL1 antibodies in NSCLC patients.
• Analysis of objective response rates in patients who have undergone prior treatments.

Main Results:

• Objective response rates for nivolumab (anti-PD1) ranged from 13-18% in pre-treated NSCLC patients.
• Objective response rates for anti-PDL1 antibodies were similar, ranging from 6-22%.
• Emerging adverse events, including autoimmune conditions, require further investigation and management protocols.

Conclusions:

• Anti-PD1 and anti-PDL1 antibodies demonstrate encouraging efficacy in a subset of NSCLC patients, particularly those with prior treatment failure.
• Ongoing Phase III trials are crucial to validate these findings.
• Further research is needed to address unresolved questions regarding treatment duration, evaluation criteria, and management of novel immune-related adverse events.